Biocure appoints Lichtenwald CFO, director

- March 1st, 2018

Biocure Technology Inc. (formerly Gravis Energy Corp.) (CSE: CURE) (the”Company” or “Biocure”) is pleased to announce that effective of today’s date, Mr. Konstatin Lichtenwald will be assuming the role of CFO and has also been appointed as a director of Biocure Technology Inc.

Biocure Technology Inc. (CSE:CURE) (formerly Gravis Energy Corp.) (the “Company” or “Biocure”) is pleased to announce that effective of today’s date, Mr. Konstatin Lichtenwald will be assuming the role of CFO and has also been appointed as a director of Biocure Technology Inc.

Ms. Julie Hajduk is resigning from the Board effective immediately. The Board would like to thank Ms. Hajduk for her tenure with the Company and her efforts with ushering it through the change of business. She will continue working with the Company on a consulting basis.

Mr, Lichtenwald will be a valued addition to Biocure as he has over ten years of finance and accounting experience, including corporate compliance, accounting and financial management and IPO, RTO services. Mr. Lichtenwald offers extensive knowledge and know-how for companies in two key financial jurisdictions, North America and German speaking parts of Europe. His accounting, financial skills offer a multi-faceted hands on approach to strategic management and problem solving.

Mr. Lichtenwald specializes in providing corporate finance, valuation, taxation, financial reporting, consulting and other accounting services to both small businesses as well as public commodity resource companies. Mr. Lichtenwald also assists in many aspects of clients’ administration, financing and other activities. Mr. Lichtenwald also worked at Ernst & Young GmbH, Germany, in the assurance department. Mr. Lichtenwald earned his bachelor of business administration degree from Pforzheim University, Germany, and holds the professional designation of Chartered Professional Accountant (CPA, CGA) and Chartered Certified Accountant (ACCA), where he is a member of Chartered Professional Accountants of B.C. and Canada as well as a member of the Association of Chartered Certified Accountants of United Kingdom. Mr. Lichtenwald has had extensive experience as a controller and CFO of numerous publicly traded and private corporations in several industries.

Mr. Collin Kim will be stepping down from his role of CFO effective immediately, but will continue to serve as a director of the Company.

The Company has granted to Mr. Lichtenwald an aggregate of 125,000 options for a two year term at an exercise price of $ 1.02 per share with 25,000 options vesting immediately and the balance on March 1, 2019.

About Biocure

Biocure is a South Korean based Bio Pharmaceutical company specializing in the development and potential commercializati on of biosimilar pharmaceutical products. Biocure is in the process of pre-clinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis (“MS”) Filgrastim is used to treat neutropenia, a  lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well —> as certain eye problems caused by diabetes. Biocure is also developing a foot and mouth disease vaccine, a hair growth production product and a breast cancer detection kit. ON BEHALF OF THE BOARD OF DIRECTORS /s/ “Sang Mok Lee” CEO and Director For further information, please contact: Biocure Technology Inc. Telephone: 604-609-7149 Certain statements in this news release, which are not historical in nature, constitute “forward looking statements” within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company’s proposed activities under the Agreement and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management’s current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements. Neither the Canadian Securities Exchange (the “CSE”) nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.


Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply